After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
SOURCE Rigel Pharmaceuticals, Inc.
Trade-Ideas LLC identified Rigel Pharmaceuticals (RIGL) as a strong on high relative volume candidate
The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.
Rigel Pharmaceuticals (RIGL) shares are down after the company announced that it was stopping the testing of its dry eye disease treatment.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.